{"id":"https://openalex.org/W1994743271","doi":"https://doi.org/10.1016/j.clpt.2005.09.002","title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses","display_name":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses","publication_year":2005,"publication_date":"2005-12-01","ids":{"openalex":"https://openalex.org/W1994743271","doi":"https://doi.org/10.1016/j.clpt.2005.09.002","mag":"1994743271","pmid":"https://pubmed.ncbi.nlm.nih.gov/16338283"},"language":"en","primary_location":{"id":"doi:10.1016/j.clpt.2005.09.002","doi":"https://doi.org/10.1016/j.clpt.2005.09.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clpt.2005.09.002","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085084466","display_name":"Gary A. Herman","orcid":"https://orcid.org/0000-0003-4433-6529","observed_orcids":["https://orcid.org/0000-0003-4433-6529"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":true,"raw_author_name":"G HERMAN","raw_affiliation_strings":["Merck & Co., Whitehouse Station, NJ 07065, USA. gary_herman@merck.com","Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Whitehouse Station, NJ 07065, USA. gary_herman@merck.com","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C STEVENS","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"C STEVENS","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087896942","display_name":"Koen Vandyck","orcid":"https://orcid.org/0000-0002-0923-8301","observed_orcids":["https://orcid.org/0000-0002-0923-8301"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"K VANDYCK","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112372714","display_name":"Arthur J. Bergman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"A BERGMAN","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110966657","display_name":"Bingming Yi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"B YI","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110178495","display_name":"M DESMET","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"M DESMET","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111519966","display_name":"Karen Snyder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"K SNYDER","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108463643","display_name":"D Hilliard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"D HILLIARD","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060581972","display_name":"Michael Tanen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"M TANEN","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114009806","display_name":"Wesley Kiyoshi Tanaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4210163344","display_name":"SGS (Belgium)","ror":"https://ror.org/05ep1jp78","country_code":"BE","type":"company","lineage":["https://openalex.org/I4210163344"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"W TANAKA","raw_affiliation_strings":["Merck & Co, Whitehouse Station, NJ","SGS Biopharma, Antwerp, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co, Whitehouse Station, NJ","institution_ids":["https://openalex.org/I1285764155"]},{"raw_affiliation_string":"SGS Biopharma, Antwerp, Belgium","institution_ids":["https://openalex.org/I4210163344"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5085084466"],"corresponding_institution_ids":["https://openalex.org/I1285764155","https://openalex.org/I4210163344"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":19.8205,"has_fulltext":false,"cited_by_count":517,"citation_normalized_percentile":{"value":0.99655584,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"78","issue":"6","first_page":"675","last_page":"688"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sitagliptin","display_name":"sitagliptin","score":1.0},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.972000002861023},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9959999918937683},{"id":"https://openalex.org/keywords/glucagon-like-peptide-1","display_name":"glucagon-like peptide-1","score":0.9169999957084656},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8980000019073486},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.8169999718666077},{"id":"https://openalex.org/keywords/dose-dependence","display_name":"dose dependence","score":0.6700000166893005},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.8840000033378601},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8289999961853027},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.8820000290870667},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.9881282448768616},{"id":"https://openalex.org/C2910260750","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin Phosphate","level":5,"score":0.7865781784057617},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7574949264526367},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.6993318200111389},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6762894988059998},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6253572106361389},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6114886999130249},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5584132671356201},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5546855330467224},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5377998352050781},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5278812646865845},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4751577079296112},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.46432986855506897},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4317702054977417},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.4137153923511505},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.27627772092819214},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.25074291229248047},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.2396656572818756},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D002096","descriptor_name":"C-Peptide","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003139","descriptor_name":"Common Cold","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D005128","descriptor_name":"Eye Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006261","descriptor_name":"Headache","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018819","descriptor_name":"Dipeptidyl Peptidase 4","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018819","descriptor_name":"Dipeptidyl Peptidase 4","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clpt.2005.09.002","doi":"https://doi.org/10.1016/j.clpt.2005.09.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clpt.2005.09.002","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:16338283","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16338283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1966523582","https://openalex.org/W1971840063","https://openalex.org/W1991477535","https://openalex.org/W1991565451","https://openalex.org/W2001739257","https://openalex.org/W2017518223","https://openalex.org/W2020267609","https://openalex.org/W2036167841","https://openalex.org/W2069150029","https://openalex.org/W2070027753","https://openalex.org/W2076880341","https://openalex.org/W2083473802","https://openalex.org/W2101405557","https://openalex.org/W2104673802","https://openalex.org/W2104763836","https://openalex.org/W2108771199","https://openalex.org/W2109157463","https://openalex.org/W2111220320","https://openalex.org/W2112228502","https://openalex.org/W2145266416","https://openalex.org/W2146232529","https://openalex.org/W2154615287"],"related_works":["https://openalex.org/W2123629330","https://openalex.org/W1967130535","https://openalex.org/W1526529090","https://openalex.org/W2054185381","https://openalex.org/W2136752386","https://openalex.org/W2793957393","https://openalex.org/W2080866420","https://openalex.org/W2797646286","https://openalex.org/W2017675780","https://openalex.org/W2002937262"],"abstract_inverted_index":{"BACKGROUND:":[0],"Sitagliptin":[1,56,171,217],"(MK-0431":[2],"[(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine])":[3],"is":[4],"an":[5,68,104,160],"orally":[6],"active,":[7],"potent,":[8],"and":[9,41,85,108,120,145,175,220],"selective":[10],"inhibitor":[11],"of":[12,25,43,47,80,117,132,186],"dipeptidyl":[13],"peptidase":[14],"IV":[15],"(DPP-IV)":[16],"currently":[17],"in":[18,51,64,103,164,191,203,212],"phase":[19],"III":[20],"development":[21],"for":[22,100,189],"the":[23,37,65,90,96,200],"treatment":[24],"type":[26],"2":[27],"diabetes.":[28],"METHODS:":[29],"Two":[30],"double-blind,":[31],"randomized,":[32],"placebo-controlled,":[33],"alternating-panel":[34],"studies":[35],"evaluated":[36],"safety,":[38],"tolerability,":[39],"pharmacokinetics,":[40],"pharmacodynamics":[42],"single":[44],"oral":[45],"doses":[46,116],"sitagliptin":[48,81,101,118,158,190,198],"(1.5-600":[49],"mg)":[50],"healthy":[52,214],"male":[53,215],"volunteers.":[54,216],"RESULTS:":[55],"was":[57,86,109,172,176],"well":[58,173],"absorbed":[59],"(approximately":[60],"80%":[61,128],"excreted":[62],"unchanged":[63],"urine)":[66],"with":[67,126,156,179],"apparent":[69],"terminal":[70],"half-life":[71],"ranging":[72],"from":[73],"8":[74],"to":[75],"14":[76],"hours.":[77],"Renal":[78],"clearance":[79],"averaged":[82],"388":[83],"mL/min":[84],"largely":[87],"uninfluenced":[88],"by":[89,113],"dose":[91],"administered.":[92],"The":[93],"area":[94],"under":[95],"plasma":[97,123,195],"concentration-time":[98],"curve":[99],"increased":[102],"approximately":[105,127,161],"dose-dependent":[106],"manner":[107],"not":[110,177],"meaningfully":[111],"influenced":[112],"food.":[114],"Single":[115],"markedly":[119],"dose-dependently":[121],"inhibited":[122],"DPP-IV":[124,133,196],"activity,":[125,197],"or":[129,139,149],"greater":[130,140,150],"inhibition":[131],"activity":[134],"occurring":[135],"at":[136,146],"50":[137],"mg":[138,148],"over":[141,151],"a":[142,152,225],"12-hour":[143],"period":[144],"100":[147],"24-hour":[153],"period.":[154],"Compared":[155],"placebo,":[157],"produced":[159],"2-fold":[162],"increase":[163],"postmeal":[165],"active":[166,204],"glucagon-like":[167,205],"peptide":[168,206],"1":[169,207],"levels.":[170],"tolerated":[174],"associated":[178],"hypoglycemia.":[180],"CONCLUSIONS:":[181],"This":[182],"study":[183],"provides":[184],"proof":[185],"pharmacologic":[187],"characteristics":[188,222],"humans.":[192],"By":[193],"inhibiting":[194],"increases":[199],"postprandial":[201],"rise":[202],"concentrations":[208],"without":[209],"causing":[210],"hypoglycemia":[211],"normoglycemic":[213],"possesses":[218],"pharmacokinetic":[219],"pharmacodynamic":[221],"that":[223],"support":[224],"once-daily":[226],"dosing":[227],"regimen.":[228]},"counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":18},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":16},{"year":2019,"cited_by_count":19},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":17},{"year":2015,"cited_by_count":28},{"year":2014,"cited_by_count":25},{"year":2013,"cited_by_count":40},{"year":2012,"cited_by_count":36}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}